bullish
Alteogen (196170 KS): Milestone Payments and Pipeline Progress Strengthen Business Growth Prospect
340 Views19 Jun 2023 18:08
SUMMARY
- Alteogen Inc (196170 KS)'s partner has submitted marketing application for Herceptin biosimilar in China. Alteogen will be entitled for royalty after the product is approved and sold in China.
- In April 2023, Alteogen announced that the company will receive additional milestone of $3 million (~KRW4 billion) from its first ALT-B4 technology transfer partner.
- Alteogen has completed patient recruitment for global phase 3 trial for Eylea biosimilar. Marketing application is expected to be filed in early 2024, with marketing expected to start from 1H25.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Alteogen: Block Deal Sale of About 3% of Shares27 Mar 2024
- Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst23 Feb 2024
- Alteogen (196170 KS): First Proprietary Product Approval in Korea To Improve Revenue Visibility05 Jan 2024
- Alteogen (196170 KS): Milestone Payments and Pipeline Progress Strengthen Business Growth Prospect19 Jun 2023
- Alteogen (196170 KS): Distinct Platform Technology; Biosimilar Pipeline; Potential Value Unlocking10 Feb 2023
x